Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Annual Costs (2025) Retail Pharmaceutical (Wegovy/Mounjaro as proxies): Without insurance: $12,000-16,800/year With insurance coverage: $1,200-3,600/year (copays) Retatrutide will likely price similarly when approved Research Peptide Suppliers: Maintenance dose (4mg weekly): $3,600-6,000/year Higher dose (8mg weekly): $7,200-12,000/year Requires self-sourcing from suppliers like Red Fox Peptides (third-party HPLC/MS testing, 98%+ purity verification, with delivery within 2-4 days for Canadian customers) Dose Reduction Strategies Many patients successfully maintain on lower doses than required for active weight loss: Lost weight on 12mg weekly
Each batch undergoes independent analytical testing to verify: Compound identity Assay accuracy Purity confirmation Mass spectrometry identity verification Microbial safety Endotoxin levels Heavy metal screening Full batch traceability Research Use Limitation Used solely for in vitro experiments Not permitted for clinical trials involving humans Not permitted for human or veterinary administration Not permitted for investigational human use Independently analysed by Liquilabs s.r.o
While tirzepatide does not selectively "target" belly fat through a unique mechanism, the substantial overall fat loss naturally includes significant reductions in abdominal adiposity
Channel that energy into activity that builds or preserves lean tissue
Disruption of its function has been identified in several neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, and prion diseases, as well as in amyotrophic lateral sclerosis (ALS)
